Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2025-07-22 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-07-22 English
Telix Reports US$204M Q2 Revenue, Up 63% YOY 6 pages 316.7KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 22 July 2025 providing a detailed update on Telix Pharmaceuticals Limited's commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). It includes unaudited revenue figures, business highlights, clinical trial updates, regulatory approvals, manufacturing updates, corporate updates including an SEC subpoena, and FY 2025 guidance. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. It contains actual financial data (revenue figures), operational and business commentary, and forward-looking guidance. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and includes substantive financial data and analysis. It is not merely an announcement of a report or a certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-07-21 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-07-09 English
Notification of cessation of securities - TLX 5 pages 16.7KB
Transaction in Own Shares Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of conditional rights to securities for Telix Pharmaceuticals Limited. It provides specific information about securities that have ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement to the ASX about changes in the company's securities, specifically the cessation of certain share rights and appreciation rights. This type of document is a notification about changes in securities ownership or status, which aligns with the category of Director's Dealing or Major Shareholding Notification. However, since it concerns cessation of securities (lapse of rights) rather than share ownership thresholds or insider trades, it fits best under the category of Transaction in Own Shares (POS), which covers company buying back or changes in its own shares or securities. The document is not a full financial report, earnings release, or management report, nor is it a regulatory filing or announcement of a report publication. Therefore, the most appropriate classification is Transaction in Own Shares (POS).
2025-07-08 English
Application for quotation of securities - TLX 7 pages 22.0KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options exercised or convertible securities converted. The document includes specifics such as the number of securities, issue dates, and whether the securities rank equally with existing securities. It does not contain financial statements, management discussion, or detailed financial results. It is not an annual or interim report, earnings release, or any form of management or audit report. Instead, it is a regulatory announcement related to capital changes, specifically the quotation of new securities on the exchange. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-07-08 English
Gozellix Receives Permanent HCPCS Code 3 pages 208.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the assignment of a permanent HCPCS code for their imaging agent Gozellix. It is a corporate news release about a regulatory and commercial milestone, not a financial report or detailed regulatory filing. The document does not contain financial statements, management discussion, or detailed regulatory compliance information. It is also not a report publication announcement since it does not mention the release or availability of a report. The content fits best as a general regulatory announcement about company developments, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2025-07-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.